Detection of circulating E/S antigens in the sera of patients with fascioliasis by IELISA: a tool of serodiagnosis and assessment of cure.
An IELISA was developed to evaluate the performance of Fasciola E/S antigens in diagnosis and cure assessment of human Fasciola infection. Twenty patients with acute (prepatent) fascioliasis and another 20 with patent infection were enrolled in the study. Patients were treated with TCZ and followed at 1, 3 and 6 months after therapy. At inspection, the sensitivity of the test to diagnose prepatent cases was 100% compared to 70% for patent infections. There was a gradual decrease of antigenaemia over the follow-up period in acute cases. In chronic cases antigen disappeared from 13 cases (65%) at 1 month; this proportion did not change at 3 or 6 months.
Shehab
A Y
AY
Department of Parasitology, Medical Research Institute, Unviersity of Alexandria, Egypt.
Hassan
E M
EM
Basha
L M
LM
Omar
E A
EA
Helmy
M H
MH
El-Morshedy
H N
HN
Farag
H F
HF
D000210:Acute-Phase Reaction; D000818:Animals; D000871:Anthelmintics / Q000627:therapeutic use; D000947:Antigens, Helminth / Q000032:analysis* / Q000097:blood; D001562:Benzimidazoles / Q000627:therapeutic use; D002908:Chronic Disease; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods*; D005209:Fasciola / Q000302:isolation & purification; D005211:Fascioliasis / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D005500:Follow-Up Studies; D006801:Humans; D012698:Serologic Tests; D000077682:Triclabendazole
D000871:Anthelmintics; D000947:Antigens, Helminth; D001562:Benzimidazoles; D000077682:Triclabendazole